delayed injection site reaction semaglutide Dermal Hypersensitivity to Semaglutide: Two Case Reports Semaglutide injection site reactions: what

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans, pharmacy chains, and the federal government.

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and Wegovy, claiming the drugs are too complex to safely replicate.

Although the evidence is scarce, it is advisable to continue treatment modalities despite improvement in EF, including device therapies, to prevent relapse and clinical deterioration

Individuals wanting to preserve muscle while losing weight

Results The primary analysis assessing the association between GLP-1 RA use and GRC or aspiration events included 20 retrospective studies with a total of 207,708 patients (23,366 GLP-1 RA users)